Koninklijke Philips Corporation N.v.

Anne Godefrida Catharina Van Brussel

Dianne Arnoldina Margaretha Wilhelmina Van Strijp

Janneke Wrobel

Ralf Hoffmann

Hendrik Jan Van Ooijen

Marcia Alves De Inda

Eveline Den Biezen-Timmermans

Robert Van Gog

Wilhelmus Franciscus Johannes Verhaegh

Joannes Baptist Adrianus Dionisius Van Zon

Johannes Baptist Adrianus Dionisius Van Zon

Jenneke Wrobel

Márcia Alves De Inda

Eveline Catharina Anna Clasina Den Biezen

Eveline Den Biezen - Timmermans

The present invention relates to methods for diagnosing, monitoring or prognosticating prostate cancer or the progression state of prostate cancer wherein said method determines the state of the prostate cancer, based on the expression level of phosphodiesterase 4D (PDE4D) variants. The invention further relates to a method of identifying an individual for eligibility for prostate cancer therapy. The invention also relates to products for the analysis of phosphodiesterase 4D (PDE4D) variants as well as pharmaceutical compositions modulating the activity and/or expression of PDE4D variants.

Methods of prostate cancer prognosis

A bioinformatics method for determining a risk score that indicates a risk that a subject will experience a negative clinical event within a certain period of time. The risk score is based on a combination of activities of two or more cellular signaling pathways in a subject, such as a human, wherein the specific cellular signaling pathways are the PI3K pathway and one or more of a Wnt pathway, an ER pathway, and an HH pathway. The invention also includes an apparatus with a digital processor configured to perform such a method, to a non-transitory storage medium storing instructions that are executable by a digital processing device to perform such a method, and to a computer program comprising program code means for causing a digital processing device to perform such a method. The invention achieves advanced prognosis of negative clinical events, for example, disease progression, recurrence, development of metastasis, or even death.

Bioinformatics process for identifying at risk subject populations

A bioinformatics method for determining a risk score that indicates a risk that a subject, in particular a human, will experience a negative clinical event within a certain period of time. The risk score is based on a unique combination of activities of two or more cellular signaling pathways in a subject, wherein the selected cellular signaling pathways are the TGF-&#x3b2; pathway and one or more of a PI3K pathway, a Wnt pathway, an ER pathway, and an HH pathway. The invention includes an apparatus with a digital processor configured to perform such a method, a non-transitory storage medium storing instructions that are executable by a digital processing device to perform such a method, and a computer program comprising program code means for causing a digital processing device to perform such a method. The bioinformatics invention allows for more accurate prognosis of specific negative clinical events in a patient with, for example, a tumor or cancer, such as disease progression, recurrence, development of metastasis, or even death.

Superior bioinformatics process for identifying at risk subject populations

Methods are described for stratifying patient risk for patients with prostate cancer and for providing a treatment recommendation to a patient based on a phosphodiesterase 4D variant 7 (PDE4D7) risk score. A diagnostic kit and a computer program product for the analysis and determination of the PDE4D7 risk score are also described.

Risk scores based on human phosphodiesterase 4D variant 7 expression

Growing community of inventors

Eindhoven, Netherlands

Anne Godefrida Catharina Van Brussel